Galenica Pharmaceuticals Inc.

No matter where you looked, pharmaceutical sales in dollar terms were down nearly 3% from 2014 to 2015; across the 350 drug-selling companies within the Scrip 100, sales fell 2.7% from $738bn in 2014

High-value, high-volume pharma M&A was predicted by many in 2016, but the big deals haven’t materialized – yet. While the volume of deals signed so far this year has continued to be robust, the total

Amgen Inc. executives didn't shed a lot of light during the company's second quarter earnings call on issues at the top of investors' minds: commercial expectations for PCSK9 inhibitor Repatha (ev

Vifor Pharma Ltd. is banking on the convenience of fewer pills per day to propel its newly approved hyperphosphatemia drug Velphoro (sucroferric oxyhydroxide) to success. But it’s unclear whether